Free Trial
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad)

Imunon Q1 2023 Earnings Report

Imunon logo
$0.83 -0.02 (-2.83%)
(As of 12/20/2024 05:51 PM ET)
Earnings HistoryForecast

Imunon Earnings Headlines

Imunon announces positive outcome of Type C CMC meeting with FDA on IMNN-001
December 20 at 12:18 PM | markets.businessinsider.com
Imunon, Inc.: IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
December 19 at 1:10 PM | finanznachrichten.de
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
December 22, 2024 | DTI (Ad)
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
December 19 at 8:05 AM | globenewswire.com
Imunon announces additional data from results from Phase 2 OVATION 2 study
December 11, 2024 | markets.businessinsider.com
Strong Potential for Imunon’s IMNN-001 in Advanced Ovarian Cancer: Promising OVATION 2 Study Results
December 11, 2024 | markets.businessinsider.com
See More Imunon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Imunon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Imunon and other key companies, straight to your email.

About Imunon

Imunon (NASDAQ:IMNN), a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

View Imunon Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles
Upcoming Earnings